|
|
|
|
| LEADER |
04023nmm a2200337 u 4500 |
| 001 |
EB001994504 |
| 003 |
EBX01000000000000001157406 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210702 ||| eng |
| 020 |
|
|
|a 9783030632342
|
| 100 |
1 |
|
|a Vermorken, Jan B.
|e [editor]
|
| 245 |
0 |
0 |
|a Critical Issues in Head and Neck Oncology
|h Elektronische Ressource
|b Key Concepts from the Seventh THNO Meeting
|c edited by Jan B. Vermorken, Volker Budach, C. René Leemans, Jean-Pascal Machiels, Piero Nicolai, Brian O’Sullivan
|
| 250 |
|
|
|a 1st ed. 2021
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2021, 2021
|
| 300 |
|
|
|a IX, 373 p. 39 illus., 33 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) -- Promising biomarkers for early diagnosis and prognosis prediction in HNS -- Biomarkers to predict radiotherapy toxicity -- Biomarkers for hypoxia, HPVness and proliferation from imaging perspective -- Mechanism of cetuximab resistance and how to overcome it -- The role of liquid biopsy for monitoring disease evolution -- NK cells in immunotherapy: how important are they? -- Biomarkers for immune modulatory treatment in HNSCC -- Primary disease (1) -- Novel approaches in surgical management of HNSCC -- The surgical approach to elderly patients with HNSCC -- The nonsurgical approach to locoregionally advanced HNSCC -- High-dose three-weekly or low-dose weekly cisplatin during radiation, what to prefer? -- Primary disease (2) -- Where and when to use induction chemotherapy? -- Prognostic role of p16/HPV in non-oropharyngeal head and neck cancer -- Is there a role for neoadjuvant targeted and immunotherapies? -- Is there a role for adjuvant targeted and immunotherapies? -- Optimal supportive measures during primary treatment -- Precision Medicine in head and neck cancer: myth or reality -- Recurrent and / or metastatic disease -- Salvage surgery: candidates, safe reconstruction, and results? -- Re-irradiation for local relapses or second primaries: when and how? -- New promising targeted agents in first and second-line settings -- Update of immune therapies in recurrent/metastatic HNSCC -- Special Issue -- Patients with rare head neck cancers: do they need a different approach? .-Nasopharynx cancer -- New epidemiological aspects -- New developments in the management of nasopharyngeal carcinoma -- New drugs for recurrent/metastatic nasopharynx cancer
|
| 653 |
|
|
|a Surgical Oncology
|
| 653 |
|
|
|a Radiotherapy
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Surgical oncology
|
| 653 |
|
|
|a Radiotherapy
|
| 700 |
1 |
|
|a Budach, Volker
|e [editor]
|
| 700 |
1 |
|
|a Leemans, C. René
|e [editor]
|
| 700 |
1 |
|
|a Machiels, Jean-Pascal
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-030-63234-2?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 520 |
|
|
|a This open access book discusses the most current issues in head and neck cancer with a focus on current trends such as biomarkers, precision medicine and immunotherapy. New approaches in the diagnosis such as liquid biopsies and imaging biomarkers to predict radiotherapy toxicity as well as approaches in the surgical management of head and neck cancers are discussed. The book discusses medical and surgical approaches in both primary, recurrent and metastatic disease and also covers approaches for rare head neck cancers. Readers will learn about the latest drug developments and epidemiological aspects in cancers ranging from head and neck squamous cell cancer to nasopharynx cancer. Edited by a team of world leaders in head and neck cancer, this volume serves as an easy reference to the head and neck oncology practitioner and provides a contemporary overview for specialists the field. The chapters are based on the latest data presented at the 7th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field
|